In particular, at this transition checkpoint, the cancer cell acquires the ability to secrete big-IGF-II and establish its autocrine stimulatory loop mediated via diversified signals that big-IGF-II exerts via the IGF-IR and the Insulin receptor fetal variant (IRA) [69]. The gene discussed is IGF2; the disease is cancer.